<?xml version="1.0" encoding="UTF-8"?>
<p>While influenza viruses and RSV circulate seasonally between beginning of fall and early spring, the increased numbers of avian influenza (H7N9) in China including highly pathogenic (HP) strains of the virus, the continued outbreaks of the HP avian influenza (HPAI) H5N1 viruses, novel variants of seasonal influenza viruses (H3N2var), and the emergence of the Middle East respiratory syndrome coronavirus (MERS-CoV) highlight the serious and important need for developing novel, more effective antiviral therapies (
 <xref rid="ref173" ref-type="bibr">Zumla et al., 2016</xref>; 
 <xref rid="ref68" ref-type="bibr">International Society for Influenza and other Respiratory Viral Diseases, 2018</xref>). This review article focuses on therapies currently under development for treatment of influenza, RSV, and MERS-CoV infections. We will briefly review drugs that have been approved by the United States Federal Drug Administration (FDA) and then drugs that are in clinical trials (
 <xref rid="fig1" ref-type="fig">Figure 1</xref>). When available, the clinical trial identifier is included.
</p>
